

Atty. Dkt. No. 016777-0528

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Daniel J. DRUCKER
Title: GLUCAGON-LIKE PEPTIDE-2
AND ITS THERAPEUTIC USE
Appl. No.: 10/042,746
Filing Date: 11/20/2002
Examiner: Unassigned
Art Unit: 1642

RECEIVED
MAR 12 2003
TECH CENTER 1600/2900

**TRANSMITTAL OF RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on January 8, 2003, in the above-identified application, transmitted herewith are the documents needed to complete the filing of the subject patent application.

Enclosed are:

- [X] Submission of Sequence Listing under 37 C.F.R. §1.821(e) (2 pages);
- [X] Copy of Transmittal of Substitute Sequence Listing with Statement filed on 06/23/1998 (1 page);
- [X] Copy of Sequence Listing filed on 06/23/1998 (4 pages);
- [X] Return Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pages).

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date March 10, 2003

By *Michele M. Simkin*

FOLEY & LARDNER
Customer Number: 22428




22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407

Facsimile: (202) 672-5399

Michele M. Simkin
Attorney for Applicant
Registration No. 34,717



EXPRESS MAIL NO.: EM 386 226 700 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: DRUCKER

Application No.: 08/632,533

Group Art Unit: 1806

Filed: April 12, 1996

Examiner: Huff, S.

For: GLUCAGON-LIKE PEPTIDE-2
AND ITS THERAPEUTIC USE

Attorney Docket No.:
8607-004-999

RECEIVED

MAR 12 2003

TECH CENTER 1600/2900

TRANSMITTAL OF SUBSTITUTE SEQUENCE LISTING

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In connection with the above-identified application,
Applicants submit herewith a substitute Sequence Listing in
paper and computer readable form.

I hereby state that the content of the paper and
computer readable copies of the substitute Sequence Listing
are the same. I hereby state that the submission herein does
not include new matter.

Respectfully submitted,

Thomas E. Friebe

Thomas E. Friebe


*by
Friebe
Reg No 30742*

29,258
(Reg. No.)

Date: June 23, 1998

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures



Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/042,746	11/20/2002	Daniel J. Drucker	016777-0528

Stephen A. Bent
Foley & Lardner, Washington Harbour
Suite 500
3000 K Street, N.W.
Washington, DC 20007-5143

RECEIVED

MAR 12 2003

TECH CENTER 1600/2900

CONFIRMATION NO. 7720

FORMALITIES LETTER



OC000000009347676

Date Mailed: 01/08/2003

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov



A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE